Merck & Co's Keytruda is poised to move even earlier in the treatment of patients with non-small cell lung cancer (NSCLC) after showing efficacy when used to prevent the cancer returning after surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback